Deep Brain Stimulation on Dual-task Gait Performance in PD
NCT05314322, Not applicable, Unknown, National Yang Ming Chiao Tung University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Deep Brain Stimulation on Dual-task Gait Performance in PD | ClinicalTrials.gov |
| NCT number | NCT05314322 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 24 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | National Yang Ming Chiao Tung University | ClinicalTrials.gov |
| Conditions | Parkinson Disease | ClinicalTrials.gov |
| Interventions | Deep brain stimulation with high frequency, Deep brain stimulation with low frequency | ClinicalTrials.gov |
| First posted | 2022-04-06 | ClinicalTrials.gov |
| Last updated | 2022-04-06 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Dual-task gait performance: Stride length | Three days after frequency adjustment | Using the OPTO gait system to evaluate stride length | ClinicalTrials.gov |
| Primary | Dual-task gait performance: Double limb support time | Three days after frequency adjustment | Using the OPTO gait system to evaluate double limb support time | ClinicalTrials.gov |
| Primary | Executive function - Inhibition control | Three days after frequency adjustment | Using the Stroop test to evaluate inhibition control | ClinicalTrials.gov |
| Primary | Executive function - Shifting attention | Three days after frequency adjustment | Using the Trail Making Test to evaluate shifting attention | ClinicalTrials.gov |
| Primary | Executive function - Working memory | Three days after frequency adjustment | Using the Digit span test to evaluate working memory | ClinicalTrials.gov |
| Primary | Cognitive function | Every 6-month up to 2 years | Using the Montreal Cognitive Assessment (MoCA) to evaluate cognitive function | ClinicalTrials.gov |
| Primary | Non-motor symptoms | Every 6-month up to 2 years | Using the Non-motor Symptoms Scale (NMSS) to non-motor symptoms | ClinicalTrials.gov |
| Secondary | Usual gait performance: Stride length | Three days after frequency adjustment | Using the OPTO gait system to evaluate stride length | ClinicalTrials.gov |
| Secondary | Usual gait performance: Double limb support time | Three days after frequency adjustment | Using the OPTO gait system to evaluate double limb support time | ClinicalTrials.gov |
| Secondary | Brain activity: Prefrontal Cortex | Three days after frequency adjustment | Using Functional near-infrared spectroscopy (fNIRS) to evaluate brain activity of Prefrontal Cortex with the formula: Hb diff=HbO-HbR | ClinicalTrials.gov |
| Secondary | Brain activity: Supplementary Motor Cortex | Three days after frequency adjustment | Using Functional near-infrared spectroscopy (fNIRS) to evaluate brain activity of Supplementary Motor Area with the formula: Hb diff=HbO-HbR | ClinicalTrials.gov |
| Secondary | Brain activity: Premotor Cortex | Three days after frequency adjustment | Using Functional near-infrared spectroscopy (fNIRS) to evaluate brain activity of Premotor Cortex with the formula: Hb diff=HbO-HbR | ClinicalTrials.gov |
| Secondary | Functional activity: Gait and balance performance | Every 6-month up to 2 years | Using the Timed up and go test to evaluate functional activity | ClinicalTrials.gov |
| Secondary | Functional activity: Lower limb function | Every 6-month up to 2 years | Using the 30s Chair Stand Test to evaluate functional activity | ClinicalTrials.gov |
| Secondary | Balance performance | Every 6-month up to 2 years | Using the Mini-BEST test to evaluate balance performance | ClinicalTrials.gov |
| Secondary | Motor symptoms | Every 6-month up to 2 years | Using the Unified Parkinson's Disease Rating Scale (UPDRS) part 3 to evaluate motor symptoms | ClinicalTrials.gov |
| Secondary | Parkinson's Disease patients' Quality of life | Every 6-month up to 2 years | Using the Parkinson's Disease Questionnaire (PDQ-39) evaluate quality of life | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)